Caldic announces acquisition of Active Pharmaceutica Ltda.

Caldic, a global value add distributor and solution provider of food ingredients and specialty chemicals for the life sciences and industrial formulation markets, is acquiring Active Pharmaceutica, a company specialized in the Brazilian compounding pharmacies sector. This transaction is fully aligned with the strategy to focus on markets that offer opportunities for high value add solutions and growth potential. 

 Since its foundation in 2007, Active Pharmaceutica has been engaged in the import, fractioning and distribution of ingredients to compounding pharmacies, enabling the creation of pharmaceuticals and nutraceuticals contributing to the overall health of their customers. With operations in the Southeast and South of Brazil, the company is one of the largest players in the region, offering a diversified portfolio that over the years has further expanded into among others hormones, nutraceuticals, pharmaceuticals, plant extracts, vitamins and minerals. In-depth knowledge and customer centric thinking enable the team to deliver customized solutions which reinforce the excellent reputation Active has in the pharma market. 

 Rodrigo Gutierrez, CEO Caldic LATAM, stated “Active Pharmaceutica has established a strong foothold in the Brazilian pharmaceutical sector with a unique value-add proposition that is fully aligned with Caldic's strategy. This acquisition will provide technical knowledge and capabilities to the Caldic organization in Latin America which, combined with our strong position in pharma in North America and Europe, will further enhance our global position in this strategic market. This is an exciting moment to welcome the Active Pharmaceutica team aboard Caldic. Together, we will continue to drive innovative solutions in the pharma business”.  

 Luis Gustavo Ferreira, CEO Active Pharmaceutica, adds: “The Active Pharmaceutica team and I are thrilled to join Caldic and be part of a global organization comprising a wide range of operations and distribution capabilities, in addition to a vast portfolio of solutions. The integration will allow us to further explore and deliver innovative solutions to the pharma market while maintaining the agile way of working that uniquely sets us apart”. 

 The transaction to acquire Active Pharmaceutica is subject to customary conditions and regulatory approvals. This process is expected to be completed in the second half of 2022.